Novo Nordisk maintains its defense in case of high-priced insulin – competitor enters settlement

Novo Nordisk upholds its defense in the case of high prices on insulin in the US. Here, prosecutors are charging pharmaceutical companies and wholesale societies with limiting market competition, Danish business media Børsen reports on Friday.